Bruker (BRKR) Projected to Release Earnings on Tuesday

Bruker (NASDAQ:BRKR) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Bruker to announce earnings of $0.38 per share and revenue of $853.5740 million for the quarter. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:00 AM ET.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same period last year, the firm earned $0.47 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, analysts expect Bruker to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bruker Price Performance

Shares of Bruker stock traded up $2.40 during trading on Tuesday, reaching $62.45. The company’s stock had a trading volume of 272,170 shares, compared to its average volume of 2,358,839. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. Bruker has a 12-month low of $28.53 and a 12-month high of $64.54. The company has a market capitalization of $9.51 billion, a P/E ratio of -261.80, a price-to-earnings-growth ratio of 1.94 and a beta of 1.29. The business has a 50 day moving average price of $56.66 and a 200-day moving average price of $46.34.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -83.33%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Los Angeles Capital Management LLC acquired a new position in shares of Bruker during the 4th quarter worth $26,000. Allworth Financial LP grew its stake in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the last quarter. Parallel Advisors LLC increased its holdings in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares in the last quarter. Summit Securities Group LLC purchased a new position in Bruker during the 4th quarter valued at about $50,000. Finally, Parkside Financial Bank & Trust increased its holdings in Bruker by 144.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 876 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Analyst Ratings Changes

BRKR has been the topic of several research analyst reports. Barclays boosted their target price on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Leerink Partners increased their price target on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Stifel Nicolaus set a $45.00 price objective on shares of Bruker in a report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $56.79.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.